The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimers disease.Linvention concerne des compositions pharmaceutiques comprenant de la caséine kinase 1 delta (CK1δ) et lutilisation desdits inhibiteurs dans le traitement de troubles neurodégénératifs tels que la maladie dAlzheimer.